Related Experiment Videos
Interleukin-10 in Epstein-Barr virus-associated post-transplant lymphomas
J L Garnier1, N Blanc-Brunat, G Vivier
1Department of Nephrology, Transplantation and Clinical Immunology, Hôpital Edouard Herriot, Lyon, France. geti@lyon151.inserm.fr
Clinical Transplantation
|September 15, 1999
Summary
Elevated interleukin-10 (IL-10) levels are linked to aggressive post-transplant lymphomas, particularly those associated with Epstein-Barr virus. This suggests IL-10 may play a role in severe lymphoma development after transplantation.
Area of Science:
- Immunology
- Oncology
- Transplantation Medicine
Background:
- Post-transplant lymphomas are a serious complication following organ transplantation.
- Interleukin-10 (IL-10) is a cytokine with known immunomodulatory functions.
- The role of IL-10 in the pathogenesis of post-transplant lymphoproliferative disorders (PTLD) requires further elucidation.
Purpose of the Study:
- To investigate the presence and significance of serum interleukin-10 (IL-10) in patients developing post-transplant lymphomas.
- To correlate IL-10 levels with clinical characteristics, Epstein-Barr virus (EBV) status, and patient outcomes.
Main Methods:
- Enzyme-linked immunosorbent assays (ELISA) were employed to quantify serum IL-10 levels.
- Serum samples were analyzed from patients diagnosed with post-transplant lymphoma or Hodgkin's disease.
- Data were compared between different patient groups, including those with and without detectable IL-10, and those with varying clinical presentations.
Main Results:
- Serum IL-10 was detected in 14 out of 19 patients with post-transplant lymphoma or Hodgkin's disease.
- Higher IL-10 levels were associated with lymphomas developing early post-transplantation and aggressive disease forms.
- Epstein-Barr virus (EBV)-positive tumors were observed in 11 of the 14 IL-10-positive patients, and 11 patients died from lymphoma.
- IL-10 was often newly detected at lymphoma diagnosis and was also found in some dialysis and stable transplant patients.
Conclusions:
- Interleukin-10 (IL-10) appears to play a role in the development of severe forms of post-transplant lymphomas.
- IL-10 may be secreted by tumor cells, contributing to lymphomagenesis.
- Caution is advised when interpreting IL-10 data in patients with chronic renal failure or on immunosuppressive therapy due to potential confounding factors.